2.55
price up icon1.59%   0.04
after-market Handel nachbörslich: 2.57 0.02 +0.78%
loading
Schlusskurs vom Vortag:
$2.51
Offen:
$2.45
24-Stunden-Volumen:
13.68M
Relative Volume:
1.70
Marktkapitalisierung:
$694.95M
Einnahmen:
$188.87M
Nettoeinkommen (Verlust:
$-400.38M
KGV:
-2.0079
EPS:
-1.27
Netto-Cashflow:
$-260.90M
1W Leistung:
+23.79%
1M Leistung:
+48.26%
6M Leistung:
+39.34%
1J Leistung:
-64.68%
1-Tages-Spanne:
Value
$2.405
$2.65
1-Wochen-Bereich:
Value
$2.015
$2.65
52-Wochen-Spanne:
Value
$1.16
$10.65

Pacific Biosciences Of California Inc Stock (PACB) Company Profile

Name
Firmenname
Pacific Biosciences Of California Inc
Name
Telefon
650-521-8000
Name
Adresse
1305 O'BRIEN DRIVE, MENLO PARK, CA
Name
Mitarbeiter
796
Name
Twitter
@pacbio
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
PACB's Discussions on Twitter

Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2023-12-14 Eingeleitet Guggenheim Neutral
2023-12-14 Eingeleitet Stephens Overweight
2023-12-13 Eingeleitet Wolfe Research Peer Perform
2023-11-17 Hochstufung UBS Neutral → Buy
2023-10-31 Hochstufung Cantor Fitzgerald Neutral → Overweight
2023-09-28 Eingeleitet Bernstein Outperform
2023-07-05 Fortgesetzt JP Morgan Overweight
2023-06-30 Eingeleitet Goldman Buy
2023-05-10 Eingeleitet Barclays Equal Weight
2023-03-31 Hochstufung TD Cowen Market Perform → Outperform
2023-02-02 Eingeleitet UBS Neutral
2023-01-20 Herabstufung Cantor Fitzgerald Overweight → Neutral
2023-01-05 Eingeleitet Scotiabank Sector Outperform
2022-01-21 Fortgesetzt Cantor Fitzgerald Overweight
2022-01-06 Fortgesetzt Piper Sandler Neutral
2021-10-15 Fortgesetzt Cowen Market Perform
2021-09-27 Eingeleitet Canaccord Genuity Buy
2021-02-11 Hochstufung Piper Sandler Neutral → Overweight
2020-11-03 Herabstufung Piper Sandler Overweight → Neutral
2020-10-02 Hochstufung JP Morgan Neutral → Overweight
2020-09-09 Eingeleitet Morgan Stanley Equal-Weight
2020-06-02 Fortgesetzt Cantor Fitzgerald Overweight
2020-03-09 Fortgesetzt Cantor Fitzgerald Overweight
2019-10-15 Hochstufung Piper Jaffray Neutral → Overweight
2019-04-02 Herabstufung Stephens Overweight → Equal-Weight
2018-10-19 Eingeleitet Cowen Outperform
2017-11-03 Herabstufung First Analysis Sec Overweight → Equal-Weight
2017-09-28 Herabstufung CL King Buy → Neutral
2016-11-03 Bestätigt Cantor Fitzgerald Buy
2016-06-27 Eingeleitet CL King Buy
2016-04-15 Eingeleitet First Analysis Sec Overweight
2016-02-04 Herabstufung Piper Jaffray Overweight → Neutral
2016-01-04 Bestätigt Cantor Fitzgerald Buy
2015-10-23 Hochstufung Piper Jaffray Neutral → Overweight
2015-08-27 Eingeleitet Cantor Fitzgerald Buy
2015-02-04 Bestätigt Maxim Group Buy
2013-09-26 Bestätigt Maxim Group Buy
2013-01-14 Bestätigt Maxim Group Buy
Alle ansehen

Pacific Biosciences Of California Inc Aktie (PACB) Neueste Nachrichten

pulisher
01:54 AM

Vanguard Group Inc's Strategic Reduction in Pacific Biosciences of California Inc - GuruFocus.com

01:54 AM
pulisher
Nov 04, 2024

Reasons to Retain PacBio Stock in Your Portfolio for Now - MSN

Nov 04, 2024
pulisher
Nov 04, 2024

Curious about Pacific Biosciences (PACB) Q3 Performance? Explore Wall Street Estimates for Key Metrics - Yahoo Finance

Nov 04, 2024
pulisher
Nov 04, 2024

Assenagon Asset Management S.A. Trims Stock Position in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat

Nov 04, 2024
pulisher
Oct 31, 2024

Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors - Yahoo Finance

Oct 31, 2024
pulisher
Oct 31, 2024

Pacific Biosciences of California (PACB) Scheduled to Post Earnings on Thursday - MarketBeat

Oct 31, 2024
pulisher
Oct 30, 2024

Pacific Biosciences (PACB): Promising Gene Editing Stock With Innovating Technology - Insider Monkey

Oct 30, 2024
pulisher
Oct 30, 2024

Volta Labs joins PacBio Compatible program to help PacBio customers scale sequencing through automated library prep - Quantisnow

Oct 30, 2024
pulisher
Oct 29, 2024

Pacific Biosciences of California (NASDAQ:PACB) Shares Up 5.7%Should You Buy? - MarketBeat

Oct 29, 2024
pulisher
Oct 29, 2024

PacBio unveils new sequencing chemistry to cut costs By Investing.com - Investing.com Canada

Oct 29, 2024
pulisher
Oct 29, 2024

PacBio Announces SPRQ Chemistry for Revio Sequencing Systems, a Major Advance Reducing the Cost of a HiFi Human Genome to less than $500 - Quantisnow

Oct 29, 2024
pulisher
Oct 29, 2024

Pacific Biosciences of California, Inc. (NASDAQ:PACB) is a favorite amongst institutional investors who own 86% - Yahoo Finance

Oct 29, 2024
pulisher
Oct 27, 2024

PACB (Pacific Biosciences of California) Cash-to-Debt : 0.55 (As of Jun. 2024) - GuruFocus.com

Oct 27, 2024
pulisher
Oct 22, 2024

PacBio Onso™ Short Read Sequencing Instrument Joins 10x Genomics Compatible Partner Program - StockTitan

Oct 22, 2024
pulisher
Oct 19, 2024

PacBio Shares Rise After NCCS Partnership for Cancer Genomics Research - MSN

Oct 19, 2024
pulisher
Oct 16, 2024

Pacific Biosciences of California (PACB) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance

Oct 16, 2024
pulisher
Oct 16, 2024

Pacific Biosciences of California (NASDAQ:PACB) Trading Down 4.8%Here's Why - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

Health Check: How Prudently Does Pacific Biosciences of California (NASDAQ:PACB) Use Debt? - Simply Wall St

Oct 16, 2024
pulisher
Oct 15, 2024

Brokerages Set Pacific Biosciences of California, Inc. (NASDAQ:PACB) PT at $4.50 - MarketBeat

Oct 15, 2024
pulisher
Oct 14, 2024

Pacific Biosciences of California (NASDAQ:PACB) Shares Gap DownHere's Why - MarketBeat

Oct 14, 2024
pulisher
Oct 12, 2024

Dimensional Fund Advisors LP Sells 2,121,331 Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat

Oct 12, 2024
pulisher
Oct 11, 2024

PacBio inks cancer research deal with Singapore's NCCS By Investing.com - Investing.com South Africa

Oct 11, 2024
pulisher
Oct 11, 2024

PacBio inks cancer research deal with Singapore's NCCS - Investing.com India

Oct 11, 2024
pulisher
Oct 11, 2024

Pacific Biosciences of California (NASDAQ:PACB) Trading 18.4% HigherHere's Why - MarketBeat

Oct 11, 2024
pulisher
Oct 11, 2024

PacBio Enters Cancer Genomics Research Collaboration in Singapore with Advanced Onso Sequencing - StockTitan

Oct 11, 2024
pulisher
Oct 10, 2024

PacBio to Report Third Quarter 2024 Financial Results on November 7, 2024 - GlobeNewswire

Oct 10, 2024
pulisher
Oct 08, 2024

Squarepoint Ops LLC Purchases Shares of 524,608 Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat

Oct 08, 2024
pulisher
Oct 05, 2024

Marshall Wace LLP Raises Stake in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat

Oct 05, 2024
pulisher
Oct 03, 2024

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) - MSN

Oct 03, 2024
pulisher
Oct 01, 2024

PacBio, A*STAR, and Macrogen Unveil State-of-the-Art Lab to Accelerate Genomics Innovation in Singapore - StockTitan

Oct 01, 2024
pulisher
Sep 30, 2024

PacBio's SWOT analysis: genomics firm faces headwinds, seeks growth - Investing.com

Sep 30, 2024
pulisher
Sep 27, 2024

PacBio Grants Equity Incentive Award to New Employee - Quantisnow

Sep 27, 2024
pulisher
Sep 24, 2024

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Shares Sold by Oracle Investment Management Inc. - MarketBeat

Sep 24, 2024
pulisher
Sep 20, 2024

Pacific Biosciences of California (NASDAQ:PACB) Shares Gap Down to $2.04 - MarketBeat

Sep 20, 2024
pulisher
Sep 20, 2024

Even With A 37% Surge, Cautious Investors Are Not Rewarding Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Performance Completely - Simply Wall St

Sep 20, 2024
pulisher
Sep 20, 2024

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World

Sep 20, 2024
pulisher
Sep 20, 2024

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives $4.50 Average Price Target from Analysts - MarketBeat

Sep 20, 2024
pulisher
Sep 20, 2024

RNA sequencing with Kinnex kits transforms University of Southampton rare disease research - Pacific Biosciences

Sep 20, 2024
pulisher
Sep 19, 2024

A stock that deserves closer examination: Pacira BioSciences Inc (PCRX) - US Post News

Sep 19, 2024
pulisher
Sep 18, 2024

OrbiMed Advisors sells shares of Passage Bio worth over $146,000 - Investing.com

Sep 18, 2024
pulisher
Sep 18, 2024

Pacific Biosciences of California (NASDAQ:PACB) Shares Gap Up to $1.87 - MarketBeat

Sep 18, 2024
pulisher
Sep 18, 2024

Stocks of Pacific Biosciences of California Inc (PACB) are poised to climb above their peers - SETE News

Sep 18, 2024
pulisher
Sep 18, 2024

Riding the Waves: A Guide to Investing in PCRX Stock - The InvestChronicle

Sep 18, 2024
pulisher
Sep 18, 2024

Processa Pharmaceuticals (NASDAQ:PCSA) Stock Price Down 0.7% - Defense World

Sep 18, 2024
pulisher
Sep 17, 2024

Health Check: Paradigm receives FDA guidance on proposed trial for dodgy knees - Stockhead

Sep 17, 2024
pulisher
Sep 17, 2024

Guess which ASX biotech stock is surging 11% on big FDA news - The Motley Fool Australia

Sep 17, 2024
pulisher
Sep 17, 2024

Analysts review Pacira BioSciences Inc’s rating - Knox Daily

Sep 17, 2024
pulisher
Sep 17, 2024

The time has not yet come to remove your chips from the table: PACS Group Inc. (PACS) - SETE News

Sep 17, 2024
pulisher
Sep 17, 2024

Insider’s View: Deciphering Pacira BioSciences Inc (PCRX)’s Financial Health Through Ratios - The Dwinnex

Sep 17, 2024
pulisher
Sep 17, 2024

Pacific Biosciences of California Inc’s Mixed Bag: Down -51.19% in 6 Months, Down 9.47% in 30 Days - The InvestChronicle

Sep 17, 2024
pulisher
Sep 17, 2024

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Shares Purchased by Daiwa Securities Group Inc. - Defense World

Sep 17, 2024

Finanzdaten der Pacific Biosciences Of California Inc-Aktie (PACB)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
medical_devices ZBH
$108.92
price up icon 0.47%
medical_devices STE
$227.44
price up icon 0.72%
medical_devices PHG
$27.08
price up icon 0.00%
$69.00
price down icon 1.00%
$88.17
price up icon 1.36%
medical_devices EW
$66.69
price up icon 0.33%
Kapitalisierung:     |  Volumen (24h):